OneSource Speci.

Why is OneSource Specialty Pharma Ltd falling/rising?

As of 23-Jul, OneSource Specialty Pharma Ltd's stock is declining by 1.19%, underperforming its sector and showing a year-to-date drop of 8.69%. Despite recent positive trends, the stock's longer-term decline and current price movements indicate short-term weakness, although increased investor participation suggests some ongoing interest.

As of 23-Jul, OneSource Specialty Pharma Ltd's stock price is currently falling, as indicated by a change of -20.0 points, which represents a decline of 1.19%. The stock has underperformed its sector today by 2.42%, and it reached an intraday low of Rs 1633, marking a decrease of 2.44%. <BR><BR>Despite a positive performance over the past week and month, with increases of 0.36% and 5.52% respectively, the year-to-date performance shows a decline of 8.69%, and the stock has fallen 17.72% over the past year. This longer-term trend may be contributing to the current downward movement in price. <BR><BR>Additionally, while the stock is trading higher than its 20-day, 100-day, and 200-day moving averages, it is lower than its 5-day and 50-day moving averages, which may indicate a short-term weakness. However, there has been a notable increase in investor participation, with delivery volume rising by 58.8% against the 5-day average, suggesting some interest in the stock despite its current decline. <BR><BR>Overall, the combination of recent price performance, underperformance against the sector, and the longer-term downward trend in stock price are key factors contributing to the current fall in OneSource Specialty Pharma Ltd's stock price.

Which are the latest news on OneSource Speci.?

Should I buy, sell or hold OneSource Specialty Pharma Ltd?

When is the next results date for OneSource Specialty Pharma Ltd?

The next results date for OneSource Specialty Pharma Ltd is July 24, 2026.

The next results date for OneSource Specialty Pharma Ltd is scheduled for July 24, 2026.

What does OneSource Speci. do?

OneSource Specialty Pharma Ltd, a small-cap company in the Pharmaceuticals & Biotechnology sector, reported net sales of 428 Cr and a net profit of 5 Cr for March 2026. The company has a market cap of INR 19,428 Cr and a debt-equity ratio of 0.24.

Overview:<BR>OneSource Specialty Pharma Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Small Cap company.<BR><BR>History:<BR>The company was incorporated in 2007 under the name Inbiopro Solutions Private Limited. It later changed its name to Stelis Biopharma Private Limited following a Scheme of Amalgamation in 2014. The latest quarterly results reported net sales and profit for March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 428 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 5 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 19,428 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: N/A<BR>- Industry P/E: 34<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.24<BR>- Return on Equity: -1.10%<BR>- Price to Book: 3.38<BR><BR>Contact Details:<BR>No Company Details Available. Registrar Address: Not available.

How big is OneSource Speci.?

As of 10th June, OneSource Specialty Pharma Ltd has a market capitalization of 19,428.00 Cr, with Net Sales of 1,421.59 Cr and a Net Profit loss of 73.80 Cr over the latest four quarters. The balance sheet as of March 2025 shows Shareholder's Funds of 5,880.58 Cr and Total Assets of 7,550.24 Cr.

As of 10th June, OneSource Specialty Pharma Ltd has a market capitalization of 19,428.00 Cr, classified as a Small Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 1,421.59 Cr. However, it experienced a loss of 73.80 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2025, showing Shareholder's Funds of 5,880.58 Cr and Total Assets of 7,550.24 Cr.

Who are the peers of the OneSource Speci.?

OneSource Speci.'s peers include Sai Life, Neuland Labs, Piramal Pharma, Astrazeneca Phar, Pfizer, ERIS Lifescience, Granules India, Caplin Point Lab, and Cohance Life. Sai Life shows the highest 1-year return at 55.07%, while OneSource Speci. has a return of -18.20%.

Peers: The peers of OneSource Speci. are Sai Life, Neuland Labs., Piramal Pharma, Astrazeneca Phar, Pfizer, ERIS Lifescience, Granules India, Caplin Point Lab, and Cohance Life.<BR><BR>Quality Snapshot: Excellent management risk is observed at Astrazeneca Phar, while Good management risk is found at Neuland Labs., Pfizer, ERIS Lifescience, Granules India, and Caplin Point Lab, and the rest have Average or Below Average management risk. Growth is Excellent at Sai Life and OneSource Speci., Good at Neuland Labs. and Piramal Pharma, and Below Average at Astrazeneca Phar, Pfizer, ERIS Lifescience, Granules India, Caplin Point Lab, and Cohance Life. Capital Structure is Excellent at Sai Life, Neuland Labs., Astrazeneca Phar, Pfizer, Granules India, Caplin Point Lab, and Cohance Life, while Below Average is noted for Piramal Pharma and OneSource Speci., and Good for ERIS Lifescience.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Sai Life at 55.07%, while Piramal Pharma has the lowest at -19.76%, with OneSource Speci. at -18.20%, indicating a performance slightly better than Piramal Pharma. Additionally, ERIS Lifescience, Astrazeneca Phar, Pfizer, Cohance Life, and Piramal Pharma all have negative six-month returns.

Are OneSource Specialty Pharma Ltd latest results good or bad?

OneSource Specialty Pharma Ltd's latest results show strong revenue growth of 47.49% to ₹428.22 crores, but a significant decline in net profit by 95.33% and compressed operating margins raise concerns about profitability and financial health. Investors should be cautious despite the positive revenue trends.

OneSource Specialty Pharma Ltd's latest results present a mixed picture, highlighting both significant challenges and some positive developments. <BR><BR>On the positive side, the company achieved a remarkable sequential revenue growth of 47.49%, reaching net sales of ₹428.22 crores, which is the highest quarterly figure on record. This suggests strong demand or successful product launches in the short term.<BR><BR>However, the profitability metrics are concerning. The net profit for Q4 FY26 was ₹4.60 crores, which represents a staggering decline of 95.33% year-on-year. Additionally, the operating margin has significantly compressed from 42.85% to 21.47% over the same period, indicating substantial pressure on profitability. The return on equity (ROE) is also weak at 2.44%, reflecting poor capital efficiency.<BR><BR>Overall, while there are signs of operational recovery in terms of revenue growth, the severe decline in profitability and margins raises critical concerns about the company's financial health and ability to sustain growth. Investors should be cautious, as the results suggest that despite the revenue increase, the company is struggling to convert that growth into meaningful profits.

How has been the historical performance of OneSource Speci.?

OneSource Speci. has shown significant growth in net sales, increasing from 128.18 Cr in March 2022 to 1,444.85 Cr in March 2025, despite facing challenges in profitability, with a profit before tax of -67.07 Cr in March 2025. Total assets rose to 7,550.24 Cr, but cash flow from operating activities remained negative at -67.00 Cr.

Answer:<BR>The historical performance of OneSource Speci. shows significant fluctuations in key financial metrics over the past four years, particularly from March 2022 to March 2025.<BR><BR>Breakdown:<BR>OneSource Speci. experienced a dramatic increase in net sales, rising from 128.18 Cr in March 2022 to 1,444.85 Cr in March 2025. This surge in total operating income followed a similar trend, moving from 171.92 Cr in March 2024 to 1,444.85 Cr in March 2025. However, the company's total expenditure also escalated, reaching 978.34 Cr in March 2025, up from 260.16 Cr in March 2024. Despite the growth in revenue, the operating profit (PBDIT) improved to 483.98 Cr in March 2025 from a loss of 84.01 Cr in March 2024. Nevertheless, the company reported a profit before tax of -67.07 Cr in March 2025, an improvement from -365.70 Cr in March 2024. The profit after tax also showed a slight recovery, with a loss of -17.28 Cr in March 2025 compared to -365.70 Cr in March 2024. The total assets of OneSource Speci. increased significantly to 7,550.24 Cr in March 2025 from 1,308.61 Cr in March 2024, while total liabilities also rose to 7,550.24 Cr. The cash flow from operating activities remained negative at -67.00 Cr in March 2025, although the net cash inflow improved to 143.00 Cr, indicating a positive shift in cash management. Overall, while OneSource Speci. has shown substantial growth in sales and operating income, it continues to face challenges in profitability and cash flow management.

Is OneSource Speci. overvalued or undervalued?

As of May 7, 2025, OneSource Specialty is considered very expensive and overvalued, with a PE ratio of 168.15 and other high valuation metrics, despite a recent stock performance of 20.62% compared to the Sensex's 3.80%.

As of 7 May 2025, the valuation grade for OneSource Specialty has moved from does not qualify to very expensive. The company is currently overvalued, with a PE ratio of 168.15, a Price to Book Value of 54.64, and an EV to EBITDA ratio of 61.77. These figures indicate a significant premium compared to its peers, such as Sun Pharmaceutical Industries Ltd., which has a PE ratio of 35.25, and Divi's Laboratories Ltd., with a PE ratio of 79.33.<BR><BR>In comparison to the broader market, OneSource Specialty's stock has shown a strong performance over the past month, returning 20.62% compared to the Sensex's 3.80%. However, despite this recent outperformance, the company's high valuation ratios suggest that it is not justified by its earnings potential, reinforcing the conclusion that it is overvalued in the current market environment.

Who are the top shareholders of the OneSource Speci.?

The top shareholders of OneSource Speci. include Tenshi Pharmaceuticals Private Limited with 17.94%, foreign institutional investors at 18.54%, and mutual funds holding 8.32%. Individual investors represent 12.96%, with Amansa Holdings Private Limited as the largest public shareholder at 3.31%.

The top shareholders of OneSource Speci. include a mix of promoters, institutional investors, and individual shareholders. The majority shareholders are the promoters, with Tenshi Pharmaceuticals Private Limited holding the highest stake at 17.94%. Additionally, mutual funds collectively hold 8.32% through 10 schemes, while foreign institutional investors (FIIs) own 18.54% across 155 entities. The highest public shareholder is Amansa Holdings Private Limited, which holds 3.31%. Individual investors account for 12.96% of the shareholding.

Has OneSource Speci. declared dividend?

No Dividend History Available